Navigation Links
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
Date:2/28/2008

ny's priorities are to advance development of its lead product candidate, Hsp90 inhibitor tanespimycin, in multiple myeloma and in metastatic breast cancer, and its lead epothilone candidate, KOS-1584, in non-small cell lung cancer, and potentially other indications. Kosan's development portfolio prioritizes clinical programs and focuses resources on product candidates that it believes represent the highest therapeutic potential and commercial value for the company in the near-term.

-- The tanespimycin TIME registration program in multiple myeloma,

Kosan's most advanced clinical program, remains on track and will

continue as planned. TIME-1, a Phase 3 pivotal trial, has been

initiated and has begun enrolling patients. Kosan plans to initiate a

supporting trial in multiple myeloma in early 2009.

-- Kosan plans to advance tanespimycin in metastatic breast cancer. To

lay the groundwork for a potential registration pathway, Kosan plans

to commence enabling studies with tanespimycin as monotherapy and as

combination therapy beginning in late 2008 and early 2009.

-- Epothilone KOS-1584 is a key asset in Kosan's pipeline. Kosan plans to

initiate a Phase 2 trial of KOS-1584 in non-small cell lung cancer in

the first quarter of 2008. Depending on available resources, Kosan may

pursue other solid tumor indications for which KOS-1584 has

demonstrated potential activity.

-- Kosan will withdraw Hsp90 inhibitor alvespimycin from development in

order to commit resources to the development of tanespimycin for the

treatment of breast cancer as a result of a comparative analysis with

tanespimycin based on several factors, including clinical experience

to date, strength of intellectual property protection and risk and

time to commercialization.

-- Kosan's motilin agonist KOS-2187 has b
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
2. Kosan Announces February 28, 2008 Conference Call and Webcast
3. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
4. Kosan Announces Third Quarter 2007 Financial Results
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Biosciences to Host Research & Development Day on October 31, 2007
7. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
8. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
9. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Wyeth Announces Executive Change in Finance Organization
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... 14 /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources Inc. ("Neptune") ... for the fiscal 2008 third quarter and,nine-month period ... on recent,strategic milestones achieved., Sales volume grew ... 29,2008 compared to the three-month period ended February ...
... 14 Phlo Corporation,(Pink Sheets: PHCP) (the "Company") ... are negotiable in connection with,market transactions and are ... Phlo common stock. This clarification was issued in ... brokers and clearing firms,will not negotiate Phlo common ...
... Inc.,(NASDAQ: VSGN ; TSX:VAS), today announced that it ... its cash burn rate and focus its,efforts on ... most,likely to provide long-term shareholder value. This plan ... series of drugs while the,Company seeks alternatives to ...
Other Biology Technology:Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 2Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 3Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 4Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2Vasogen Announces Implementation of Strategic Restructuring Plan 2Vasogen Announces Implementation of Strategic Restructuring Plan 3Vasogen Announces Implementation of Strategic Restructuring Plan 4Vasogen Announces Implementation of Strategic Restructuring Plan 5
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... first key step in the creation of new life, according ... 27 October 2005). , The gene, known as HIRA, 'chaperones' ... an egg, giving it a crucial role in the most ... mutation of this gene in the maternal (mother's) genome explains ...
... year's groundbreaking toxicological study on water-soluble buckyballs, researchers ... Nanotechnology (CBEN) find that water-soluble carbon nanotubes are ... research finds that nanotubes, like buckyballs, can be ... findings come from the first toxicological studies of ...
... a biologist at the University of California, San Diego that ... found that females of the species Uca crenulata may check ... before finally deciding on a mate. , “As far as ... as many candidates as the California fiddler crab,?said Catherine deRivera, ...
Other Biology News:Scientists unpick genetics of first 15 minutes of life 2Modifications render carbon nanotubes nontoxic 2Modifications render carbon nanotubes nontoxic 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
ASCIZ...
Biology Products: